Holen Sie sich die Stockscreener-App
3.40
2.72%
0.09
Handel nachbörslich:
3.40
Schlusskurs vom Vortag:
$3.31
Offen:
$3.32
24-Stunden-Volumen:
84,301
Relative Volume:
0.18
Marktkapitalisierung:
$129.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-78.92M
KGV:
-1.6667
EPS:
-2.04
Netto-Cashflow:
$-72.87M
1W Leistung:
+9.32%
1M Leistung:
-2.30%
6M Leistung:
-0.29%
1J Leistung:
-36.92%
1-Tages-Spanne:
$3.20
$3.43
1-Wochen-Bereich:
$3.11
$3.43
52-Wochen-Spanne:
$2.47
$9.24
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Firmenname
Vigil Neuroscience Inc
Sektor
Branche
Telefon
857-254-4445
Adresse
100 FORGE ROAD, WATERTOWN
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2022-09-16 | Eingeleitet | Wedbush | Outperform |
| 2022-08-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Eingeleitet | Jefferies | Buy |
| 2022-02-01 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vigil Neuroscience Inc Aktie (VIGL) Neueste Nachrichten
Ensign Peak Advisors Inc Buys 166,442 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in September - MarketBeat
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Certified Advisory Corp Grows Stake in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Purchased by Harmony Asset Management LLC - Defense World
Evergreen Capital Management LLC Sells 380 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Circle Wealth Management LLC Acquires 383 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Garden State Investment Advisory Services LLC Acquires 743 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Vicor Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – VICR - ForexTV.com
Vigil Neuroscience shares maintain Outperform rating on positive FDA update - Investing.com
WCG Wealth Advisors LLC Has $3 Million Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Bradley Foster & Sargent Inc. CT Cuts Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
1,275 Shares in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Bought by One Capital Management LLC - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Sold by ProVise Management Group LLC - Defense World
Vigil Neuroscience shares maintain Outperform rating on positive FDA update By Investing.com - Investing.com Australia
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Clinical Trials Arena
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Yahoo Finance
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com Canada
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com South Africa
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - ForexTV.com
Vigil stock gains as FDA removes partial hold (NASDAQ:VIGL) - Seeking Alpha
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com India
Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data - TipRanks
Vigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment Trial - MarketWatch
Vigil Neuroscience rises as FDA lifts partial hold on Alzheimer’s disease trial - XM
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - GlobeNewswire
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - StockTitan
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com
The Neuroscience Market Research Explores 2024: Advancing Brain Research and Therapeutics - WhaTech
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - GlobeNewswire
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - StockTitan
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 23.7% in August - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Trading 5% Higher - MarketBeat
Neurodegenerative Disorder Therapeutics Market Insights Discussed Regarding Size And Outlook 2024-2033 - WhaTech
A stock that deserves closer examination: Vigil Neuroscience Inc (VIGL) - US Post News
You might want to take a look at Vigil Neuroscience Inc (VIGL) now - SETE News
Vigil Neuroscience to Present at Upcoming September Investor Conferences - GlobeNewswire
Vigil Neuroscience to Present at Upcoming September Investor Conferences - StockTitan
Vanguard Group Inc. Acquires 95,276 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Q3 2024 EPS Estimates for Vigil Neuroscience, Inc. Decreased by Analyst (NASDAQ:VIGL) - MarketBeat
Research Analysts Offer Predictions for Vigil Neuroscience, Inc.’s Q3 2024 Earnings (NASDAQ:VIGL) - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by HC Wainwright - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.4% in July - MarketBeat
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock - Investing.com India
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock By Investing.com - Investing.com Canada
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock By Investing.com - Investing.com UK
Vigil Neuroscience (NASDAQ:VIGL) Price Target Cut to $16.00 by Analysts at Guggenheim - Defense World
HC Wainwright Analysts Cut Earnings Estimates for Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
FY2027 EPS Estimates for Vigil Neuroscience, Inc. Reduced by HC Wainwright (NASDAQ:VIGL) - Defense World
Finanzdaten der Vigil Neuroscience Inc-Aktie (VIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):